Symeres, a global contract research, development and manufacturing organization, has acquired DGr Pharma, a consultancy focused on early-stage drug development, to strengthen its regulatory expertise and expand integrated services for biopharma clients. The deal is supported by Keensight Capital, a private equity manager specialising in pan-European growth buyouts.

Founded in 2018 and based in the Netherlands, DGr Pharma offers regulatory strategy and consultancy for pre-clinical and clinical drug development. Its services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. The company has experience with small and large molecules, including antibodies, ADCs and oligonucleotides.

DGr Pharma’s pharmacokinetic data analysis services operate under Good Clinical Practice and Good Laboratory Practice, aligning with Symeres’ integrated offerings such as ADME. The GLP accreditation supports regulatory readiness and improves efficiency for IND submissions.

Guillaume Jetten, ceo of Symeres, said: “This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. DGr Pharma’s expertise enhances our scientific capabilities, allowing us to better support our clients’ evolving needs and reinforce Symeres’ position as a partner of choice in the global biopharma market.”

Kees Groen, founder and ceo of DGr Pharma, added: “This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres’ commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth.”

Amit Karna, partner at Keensight Capital, added: “We are proud to support Symeres with this specialized acquisition, which will extend the company’s capabilities into highly complementary services and attractive drug classes. We look forward to continuing to support the Symeres team as they selectively broaden the company’s offering for their blue-chip biopharma clients.”